Moderna, Inc. research snapshot
MRNA AI stock analysis reads Moderna, Inc. as a post-COVID mRNA platform company with a strong cash position, negative earnings, and high option value across respiratory, oncology, rare disease, and latent-virus programs. At the August 2, 2026 data cutoff, MRNA closed at $54.82 on July 31, 2026, the same day it reported second quarter results, with a market capitalization near $21.89 billion. The Q2 2026 report showed revenue of $145 million above consensus, a GAAP net loss that narrowed 5% year over year to $782 million, and an improved 2026 outlook with year-end cash guidance raised to $4.7 billion to $5.2 billion. The offsetting negatives include a norovirus Phase 3 interim that missed early success criteria, continued COVID demand weakness, negative earnings, and a consensus analyst price target of $49.47 that sits below the current price. The AI view is not a simple buy signal because Moderna remains loss-making and the outcome depends on the August 5 flu PDUFA, intismeran melanoma data, PA data, cash burn control, and commercial execution. This page uses scenarios, technical levels, and source-backed facts. It is informational research, not investment advice.
Current price
$54.82
Market cap
$21.89 billion
AI score
48 / 100
Rating
Cash-rich turnaround with high event risk and negative earnings
Trend status
Downtrend below the 50-day average, above the 200-day average
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Moderna owns a validated mRNA platform, but current revenue is still concentrated in COVID and respiratory vaccines while the broader pipeline has not yet rebuilt durable earnings. | Medium |
| Moat | The moat comes from mRNA know-how, lipid nanoparticle delivery, manufacturing scale, regulatory experience, patents, and clinical data, but competitors and large pharma partners can contest each attractive market. | Medium |
| Management | CEO Stephane Bancel and the team delivered Q2 revenue above consensus, a narrower net loss, an improved 2026 cash outlook, and two senior hires, but capital allocation now depends on cutting cash burn while funding enough pipeline shots on goal. | Medium |
| Financial trend | Q2 2026 revenue was $145 million with a $782 million net loss, cash and investments were $6.9 billion at June 30, 2026, and the company guided to up to 10% revenue growth with $4.7 billion to $5.2 billion year-end cash. | High |
| Valuation | At $54.82, MRNA traded near 9.8x trailing revenue per share with negative EPS, so P/E is not useful. Net cash near $5.62 billion, about $14.08 per share, cushions part of the downside. | Medium |
| Technical trend | Price closed below the 50-day moving average near $58.41 and above the 200-day moving average near $44.86, with RSI near 41, after a slide from the $85.60 52-week high. | Medium |
| Risk level | Risk is high because vaccine demand, competition, R&D intensity, clinical readouts, approvals, cash burn, and short interest near 13% of shares outstanding can change the equity story quickly. | High |
| AI confidence | The descriptive research is well supported. The price forecast has lower confidence because a few pipeline and regulatory events can dominate fundamentals. | Medium |
| Investment certainty | Investment certainty is below business-data certainty. MRNA needs evidence that non-COVID products can create repeatable revenue before the thesis becomes high conviction. | Low-medium |
MRNA AI stock forecast
The MRNA AI stock forecast uses scenario ranges rather than a precise price prediction. Negative EPS makes a normal P/E target unusable, so the practical forecast depends on the August 5 flu PDUFA, flu uptake, norovirus progress, intismeran melanoma and PA data, COVID demand, cash burn, and whether investors assign value to the mRNA platform beyond COVID. The 23-analyst consensus is Hold with an average target of $49.47 and a range of $25 to $79.
$65 to $80
More likely if mFLUSIVA and mRNA-1010 gain U.S. approval and flu uptake is strong, intismeran melanoma Phase 3 interim data is positive with Merck, PA registrational data is favorable, COVID demand stabilizes, and cash burn falls toward the lowered operating cost guidance.
$46 to $58
More likely if flu approval happens but uptake builds gradually, norovirus adds a fourth cohort without clear timing, respiratory demand stays seasonal, pipeline readouts are mixed, and investors wait for clearer 2027 to 2028 product contribution before raising targets.
$34 to $44
More likely if flu uptake disappoints, the norovirus delay becomes a reset, COVID and RSV demand weaken further, clinical or regulatory timelines slip, cash burn stays elevated, or the market discounts the pipeline until approved non-COVID revenue becomes visible.
MRNA AI technical analysis
MRNA AI technical analysis is fragile as of the August 2, 2026 cutoff. StockAnalysis data showed MRNA near $54.82 on July 31, 2026, below the 50-day moving average of $58.41 and above the 200-day moving average of $44.86, with RSI near 41 and a 52-week range of $22.28 to $85.60. The stock broke down from the $85.60 high after a JPMorgan Sell rating and the Q2 report, so the short-term trend is weak while the medium-term uptrend above the 200-day average is still intact but vulnerable.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $54.82 | Close used for July 31, 2026 market cap, valuation, and technical analysis. |
| Near support | $52 to $54 | The July 31 low area near $54.71 and the round $52 zone form the first pullback support to monitor. |
| Secondary support | $48 to $50 | The consensus analyst target near $49.47 and the round $50 mark the next downside reference. |
| Long-term support | $44 to $46 | The 200-day moving average near $44.86 is the major trend line. A break below it would challenge the recovery thesis. |
| Resistance | $58 to $60 | The 50-day moving average near $58.41 and the round $60 level mark the first upside hurdle. |
| Secondary resistance | $68 to $70 | The July breakdown zone is the next resistance if price reclaims the 50-day average. |
| Major resistance | $85 to $86 | StockAnalysis lists the 52-week high near $85.60, the outer upside reference. |
| Momentum | Weak short-term, neutral long-term | Price below the 50-day average with RSI near 41 suggests short-term momentum is weak, while the 200-day average still holds. |
| Volume | High liquidity, news-driven spikes | Volume should be checked around the August 5 PDUFA, earnings, ACIP or FDA events, oncology updates, and vaccine demand commentary. |
| Volatility | High biotech volatility | MRNA remains more volatile than a mature pharma stock, with beta near 0.90 and short interest near 13% of shares outstanding. |
| Invalidation | Close below $44.86 | A decisive break below the 200-day average weakens the medium-term uptrend. A close below $50 raises downside risk toward the target zone. |
MRNA AI trading strategy
The MRNA AI trading strategy is a rules-based framework for a volatile biotech platform stock. It is not personal advice and should be paired with live quotes, filings, position sizing, clinical calendars, FDA updates, and cash burn monitoring.
Watch for MRNA to reclaim the 50-day moving average near $58 with confirming volume and no negative vaccine or pipeline news. The medium-term trend filter is the 200-day average near $44.86.
A close below $50 should reduce confidence. A close below the 200-day moving average near $44.86 would require a full trend and thesis reset.
If MRNA pulls back toward the $48 to $52 zone without a new clinical, regulatory, or cash burn problem, compare the price drop with fresh evidence on flu, RSV, COVID, norovirus, and oncology progress before treating it as noise.
Do not treat every drop as technical noise. The norovirus miss shows that pipeline delays can turn a support level into a fundamental break.
Track quarterly cash and investments, operating loss, 2026 revenue guidance, the August 5 flu PDUFA, flu uptake, intismeran melanoma and PA data, norovirus cohort progress, respiratory vaccine sales, and restructuring progress.
Reduce confidence if cash burn stays high while non-COVID revenue does not scale, or if pipeline value depends on repeated timeline extensions.
Investment research summary
Moderna tries to turn a programmable mRNA platform into approved medicines. Customers pay when the platform produces vaccines or therapeutics with clinical benefit, regulatory approval, manufacturing reliability, and acceptable reimbursement.
The moat is real but not settled. Moderna has mRNA know-how, delivery science, manufacturing experience, patents, and regulatory learning, yet Pfizer, BioNTech, GSK, Sanofi, Merck-partnered programs, and other biotech firms can compete where demand is attractive.
The thesis fails if respiratory vaccine demand keeps shrinking, if the norovirus delay becomes a reset, if cash burn lasts longer than expected, if the flu launch or intismeran readout disappoints, or if competitors produce better efficacy, safety, convenience, or price.
Management proved it could scale under extreme COVID urgency and is now showing cost discipline with a narrower loss and an improved cash outlook. The harder test is converting pipeline optionality into durable non-COVID revenue while cash declines.
mRNA remains part of a long-term biotech shift toward faster programmable medicines, cancer immunotherapy, and precision vaccines. The industry trend is favorable, but commercial adoption is uneven and clinical failure rates remain high.
With negative EPS, P/E does not provide a useful margin-of-safety signal. Investors are paying for cash runway, approved respiratory products, and pipeline option value, so the margin of safety improves only if cash burn falls and non-COVID proof points become harder to dispute.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| MRNA price | $54.82 close on July 31, 2026 | StockAnalysis.com quote snapshot | August 2, 2026 |
| Market capitalization | $21.89 billion, verified as $54.82 x 399.24 million shares | financial_rigor.py and StockAnalysis market cap data | August 2, 2026 |
| Q2 2026 revenue | $145 million | Moderna Q2 2026 press release via Accesswire | August 2, 2026 |
| Q2 2026 net loss | $782 million net loss, GAAP EPS of $(1.97) | Moderna Q2 2026 press release | August 2, 2026 |
| Cash and investments | $6.9 billion at June 30, 2026 | Moderna Q2 2026 press release | August 2, 2026 |
| FY2025 revenue | $1.944 billion | StockAnalysis.com annual financials and Moderna FY2025 results | August 2, 2026 |
| FY2025 net loss | $2.822 billion net loss | StockAnalysis.com annual financials | August 2, 2026 |
| Shares outstanding | 399.24 million shares used for market cap verification | StockAnalysis.com share statistics | August 2, 2026 |
| Valuation math | P/S about 9.82x; P/E not meaningful because EPS is negative; net cash near $5.62 billion | financial_rigor.py valuation verification and StockAnalysis statistics | August 2, 2026 |
| Moving averages | 50-day near $58.41, 200-day near $44.86, RSI near 40.70 | StockAnalysis.com statistics | August 2, 2026 |
| 52-week range | $22.28 to $85.60 | StockAnalysis.com overview | August 2, 2026 |
| Analyst consensus | Hold, average target $49.47, range $25 to $79 | StockAnalysis.com forecast, S&P Global and TipRanks data | August 2, 2026 |
| Short interest | 52.40 million shares, 13.13% of shares outstanding | StockAnalysis.com statistics | August 2, 2026 |
| 2026 guidance | Up to 10% revenue growth and year-end cash of $4.7 billion to $5.2 billion | Moderna Q2 2026 press release and earnings call transcript | August 2, 2026 |
This MRNA AI stock analysis page is an informational research tool only. It is not investment advice, financial advice, tax advice, a recommendation, or a promise of future returns. Forecast ranges are scenarios based on available public filings, quote snapshots, technical data, and third-party sources as of August 2, 2026. They may be wrong, incomplete, or outdated after new earnings, vaccine demand updates, clinical data, regulatory decisions, cash burn changes, market moves, or macro conditions.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
